BioUtah president & CEO Kelvyn Cullimore interviews Renalytix CEO James McCullough to discuss the growth, innovations of Renalytix, a diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs. Topics discussed include:
Kidney diseases prognostics
Working with the FDA to achieve regulatory hurdles
Alternate means of funding a start-up life sciences company
Life sciences companies locating in Utah
Much more
James McCullough Bio:
James McCullough has served as our co-founder and chief executive officer since Renalytix's inception. Mr. McCullough has leadership experience building emerging technology companies in both the public and private sectors with specific expertise in the life-sciences industry. From 2008 to 2014, he served as chief executive officer of Exosome Diagnostics Inc., a venture backed personalized medicine company developing non-invasive liquid biopsy diagnostics in cancer that was acquired by Bio-Techne Corporation in 2018. Since 2014, Mr. McCullough has also served as a managing partner of Renwick Capital, LLC, a management consulting firm specializing in assisting emerging healthcare technology companies with strategic planning and business execution. He received his B.A. from Boston University and an MBA from Columbia Business School.
